Anthony M Manning

US Patent:

20230049725, Feb 16, 2023

Filed:

Apr 28, 2022

Appl. No.:

17/661070

Inventors:

- Titusville NJ, US
Sucharita Roy - Acton MA, US
Nathaniel Washburn - Littleton MA, US
Marilyn Kehry - San Diego CA, US
David J. King - Encinitas CA, US
Anthony Manning - Cambridge MA, US
James Meador, III - Framingham MA, US
Jan Hillson - , US

International Classification:

C07K 16/28
A61P 37/02

Abstract:

The present application features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.

US Patent:

20210238275, Aug 5, 2021

Filed:

Jul 31, 2017

Appl. No.:

16/321801

Inventors:

Sucharita Roy - Acton MA, US
Nathaniel Washburn - Cambridge MA, US
Marilyn Kehry - San Diego CA, US
David J. King - Encinitas CA, US
Anthony Manning - Cambridge MA, US
James Meador, III - Framingham MA, US
Jan Hillson - Cambridge MA, US

International Classification:

C07K 16/28
A61P 37/02

Abstract:

The present application features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.

US Patent:

20210147549, May 20, 2021

Filed:

Jul 11, 2019

Appl. No.:

17/259067

Inventors:

- Cambridge MA, US
Daniel Ortiz - Stoneham MA, US
Anthony Manning - Cambridge MA, US
Laura Rutitzky - Somerville MA, US

International Classification:

C07K 16/28

Abstract:

Fc-antigen binding constructs having a PD-L1 binding domain and two or more Fc domains are described as are methods for using such constructs. Also described are polypeptides making up such constructs. Fc domain monomers that are included in the constructs can include amino acid substitutions that promote homodimerization or heterodimerization.

US Patent:

20200299382, Sep 24, 2020

Filed:

Mar 20, 2020

Appl. No.:

16/825066

Inventors:

- Cambridge MA, US
David J. King - Encinitas CA, US
Leona E. Ling - Winchester MA, US
James Meador, III - Framingham MA, US
Sucharita Roy - Tyngsboro MA, US
Anthony Manning - Cambridge MA, US

International Classification:

C07K 16/28

Abstract:

The present invention features antibodies that have high binding affinity to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject.

US Patent:

20200055921, Feb 20, 2020

Filed:

Nov 1, 2019

Appl. No.:

16/671595

Inventors:

- Cambridge MA, US
Leona E. Ling - Cambridge MA, US
Carlos J. Bosques - Cambridge MA, US
Anthony Manning - Cambridge MA, US
Ganesh Kaundinya - Cambridge MA, US

International Classification:

C07K 16/00
G01N 33/68
C07K 16/06

Abstract:

The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an α 1,3 and/or α 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuA-α 2,6-Gal or NeuAc-α 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in pert, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.

US Patent:

20190048417, Feb 14, 2019

Filed:

Sep 30, 2016

Appl. No.:

15/765061

Inventors:

- Cambridge MA, US
Patrick Halvey - Cambridge MA, US
Kevin McConnell - Cambridge MA, US
Victor Farutin - Cambridge MA, US
Ishan Capila - Cambridge MA, US
Leona E. Ling - Cambridge MA, US
Anthony Manning - Cambridge MA, US

Assignee:

Momenta Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C12Q 1/6883
A61K 38/19
A61K 9/00
A61P 37/06
A61P 29/00

Abstract:

The present invention features methods of treating a subject having an autoimmune disease and/or inflammation including determining the genotype, and/or the glycophenotype of the subject and administering to the subject an Fc-activity modulating agent or an anti-TNFα agent based on the genotype and/or the glycophenotype of the subject. The invention also features methods of predicting the responsiveness of a patient to an anti-TNFα treatment by identifying a patient having inflammation or an autoimmune disease, determining the genotype, or glycophenotype of the subject, and selecting the patient for treatment with an Fc-activity modulating agent or an anti-TNFα agent based on the genotype and/or the glycophenotype of the subject.

US Patent:

20180016334, Jan 18, 2018

Filed:

Jan 29, 2016

Appl. No.:

15/546870

Inventors:

- Cambridge MA, US
David J. KING - Encinitas CA, US
Leona E. LING - Winchester MA, US
James MEADOR, III - Framingham MA, US
Sucharita ROY - Tyngsboro MA, US
Anthony MANNING - Cambridge MA, US

International Classification:

C07K 16/28
A61K 39/00

Abstract:

The present invention features antibodies that have high binding affinity to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject.

US Patent:

20160090409, Mar 31, 2016

Filed:

May 13, 2014

Appl. No.:

14/890865

Inventors:

- Cambridge MA, US
Leona E. LING - Winchester MA, US
Carlos J. BOSQUES - Arlington MA, US
Anthony MANNING - Cambridge MA, US
Ganesh KAUNDINYA - Bedford MA, US

International Classification:

C07K 16/00
G01N 33/68

Abstract:

The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an α 1,3 and/or α 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuAc-α 2,6-Gal or NeuAc-α 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in part, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.